Dexametasona o hidrocortisona intravenosa como profilaxis de cefalea postpunción dural
Objective: to determine the efficacy of intravenous dexamethasone or hydrocortisone as prophylaxis of post-dural punc-ture headache in patients who underwent surgery from January to December 2018. It was an experimental, descriptive, prospective, cross-sectional and correlational investigation. The...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
2021
|
| Subjects: | |
| Online Access: | https://dialnet.unirioja.es/servlet/oaiart?codigo=8056950 |
| Source: | RECIMUNDO: Revista Científica de la Investigación y el Conocimiento, ISSN 2588-073X, Vol. 5, Nº. 3, 2021, pags. 52-65 |
| Tags: |
Add Tag
No Tags: Be the first to tag this record
|
| id |
dialnet-ar-18-ART0001475436
|
|---|---|
| record_format |
dialnet
|
| institution |
Dialnet
|
| collection |
Dialnet AR
|
| source |
RECIMUNDO: Revista Científica de la Investigación y el Conocimiento, ISSN 2588-073X, Vol. 5, Nº. 3, 2021, pags. 52-65
|
| language |
Spanish
|
| topic |
Cefalea postpunción dural
profilaxis hidrocortisona dexametasona pacientes gestantes anestesia conductiva Post-dural puncture headache prophylaxis hydrocortisone dexamethasone pregnant patients conductive anesthesia |
| spellingShingle |
Cefalea postpunción dural
profilaxis hidrocortisona dexametasona pacientes gestantes anestesia conductiva Post-dural puncture headache prophylaxis hydrocortisone dexamethasone pregnant patients conductive anesthesia Calle Gómez, Marco A. Devonish, Nidia Gurumendi España, Ingrid Esmeralda Borja Santillán, Maritza Alexandra Dexametasona o hidrocortisona intravenosa como profilaxis de cefalea postpunción dural |
| description |
Objective: to determine the efficacy of intravenous dexamethasone or hydrocortisone as prophylaxis of post-dural punc-ture headache in patients who underwent surgery from January to December 2018. It was an experimental, descriptive, prospective, cross-sectional and correlational investigation. The sample of elective patients (n = 60) was divided into three groups (A: control (n = 20), B: Hydrocortisone 500mg EV (n = 20) and C: Dexamethasone 16mg EV (n = 20)). Descriptive statistics. Results: statistically, the groups in terms of age (A: 66; B: 57 and C: 44), weight (A: 68 kg; B: 67 and C: 57) and height (A: 158 cm; B: 155 and C: 168) were similar; A 25G Sprotte needle, with ASA I risk, was used in all patients; In the control group (A), symptoms of CPPD were observed in 10% of the patients: orthostatic headache, bilateral headache, neck stiffness, tinnitus, photophobia, diplopia, nausea, vomiting, dizziness and previous lumbar puncture. . In the Hydro-cortisone Group (B) no CPPD symptoms were observed and in the dexamethasone group (C) no CPPD symptoms were observed. The average appearance of symptoms was between 19 to 28 hours later, without any adverse reaction. Conclu-sions: the use of both drugs is equally effective as a prophylaxis of post-dural puncture headache.
|
| format |
Article
|
| author |
Calle Gómez, Marco A.
Devonish, Nidia Gurumendi España, Ingrid Esmeralda Borja Santillán, Maritza Alexandra |
| author_facet |
Calle Gómez, Marco A.
Devonish, Nidia Gurumendi España, Ingrid Esmeralda Borja Santillán, Maritza Alexandra |
| author_sort |
Calle Gómez, Marco A.
|
| title |
Dexametasona o hidrocortisona intravenosa como profilaxis de cefalea postpunción dural
|
| title_short |
Dexametasona o hidrocortisona intravenosa como profilaxis de cefalea postpunción dural
|
| title_full |
Dexametasona o hidrocortisona intravenosa como profilaxis de cefalea postpunción dural
|
| title_fullStr |
Dexametasona o hidrocortisona intravenosa como profilaxis de cefalea postpunción dural
|
| title_full_unstemmed |
Dexametasona o hidrocortisona intravenosa como profilaxis de cefalea postpunción dural
|
| title_sort |
dexametasona o hidrocortisona intravenosa como profilaxis de cefalea postpunción dural
|
| publishDate |
2021
|
| url |
https://dialnet.unirioja.es/servlet/oaiart?codigo=8056950
|
| _version_ |
1767463992360435712
|
| spelling |
dialnet-ar-18-ART00014754362023-05-30Dexametasona o hidrocortisona intravenosa como profilaxis de cefalea postpunción duralCalle Gómez, Marco A.Devonish, NidiaGurumendi España, Ingrid EsmeraldaBorja Santillán, Maritza AlexandraCefalea postpunción duralprofilaxishidrocortisonadexametasonapacientes gestantesanestesia conductivaPost-dural puncture headacheprophylaxishydrocortisonedexamethasonepregnant patientsconductive anesthesiaObjective: to determine the efficacy of intravenous dexamethasone or hydrocortisone as prophylaxis of post-dural punc-ture headache in patients who underwent surgery from January to December 2018. It was an experimental, descriptive, prospective, cross-sectional and correlational investigation. The sample of elective patients (n = 60) was divided into three groups (A: control (n = 20), B: Hydrocortisone 500mg EV (n = 20) and C: Dexamethasone 16mg EV (n = 20)). Descriptive statistics. Results: statistically, the groups in terms of age (A: 66; B: 57 and C: 44), weight (A: 68 kg; B: 67 and C: 57) and height (A: 158 cm; B: 155 and C: 168) were similar; A 25G Sprotte needle, with ASA I risk, was used in all patients; In the control group (A), symptoms of CPPD were observed in 10% of the patients: orthostatic headache, bilateral headache, neck stiffness, tinnitus, photophobia, diplopia, nausea, vomiting, dizziness and previous lumbar puncture. . In the Hydro-cortisone Group (B) no CPPD symptoms were observed and in the dexamethasone group (C) no CPPD symptoms were observed. The average appearance of symptoms was between 19 to 28 hours later, without any adverse reaction. Conclu-sions: the use of both drugs is equally effective as a prophylaxis of post-dural puncture headache.El objeto de este artículo es determinar la eficacia de dexametasona o hidrocortisona endovenosa como profilaxis de ce-falea postpunción dural en pacientes intervenidos quirúrgicamente de enero a diciembre de 2018. Fue una investigación experimental, descriptiva, prospectiva, transversal y correlacional. La muestra de pacientes electivos (n=60) se dividió en tres grupos (A: control (n=20), B: Hidrocortisona 500mg EV (n=20) y C: Dexametasona 16mg EV (n=20)). Estadística tipo descriptiva. Resultados: estadísticamente, los grupos en cuánto a edad (A: 66; B: 57y C: 44 ), peso (A: 68 kg; B: 67 y C: 57) y talla (A: 158 cms; B: 155 y C: 168) fueron similares; se usó en todas las pacientes aguja Sprotte de calibre 25G, con riesgo ASA I; en el grupo control (A) se observaron en el 10% de los pacientes (2) síntomas de CPPD: cefalea ortostática, cefalea bilateral, rigidez de nuca, tinnitus, fotofobia, diplopía, náuseas, vómitos, mareos y realización de punción lumbar previa. En el Grupo de Hidrocortisona (B) no se observaron síntomas de CPPD y en el grupo dexametasona (C) no se observaron síntomas de CPPD. El promedio de aparición de síntomas fue entre 19 a 28 horas después, sin ninguna reac-ción adversa. Conclusiones: el empleo de ambos medicamentos tiene la misma efectividad como profilaxis de la cefalea postpunción dural.2021text (article)application/pdfhttps://dialnet.unirioja.es/servlet/oaiart?codigo=8056950(Revista) ISSN 2588-073XRECIMUNDO: Revista Científica de la Investigación y el Conocimiento, ISSN 2588-073X, Vol. 5, Nº. 3, 2021, pags. 52-65spaLICENCIA DE USO: Los documentos a texto completo incluidos en Dialnet son de acceso libre y propiedad de sus autores y/o editores. Por tanto, cualquier acto de reproducción, distribución, comunicación pública y/o transformación total o parcial requiere el consentimiento expreso y escrito de aquéllos. Cualquier enlace al texto completo de estos documentos deberá hacerse a través de la URL oficial de éstos en Dialnet. Más información: https://dialnet.unirioja.es/info/derechosOAI | INTELLECTUAL PROPERTY RIGHTS STATEMENT: Full text documents hosted by Dialnet are protected by copyright and/or related rights. This digital object is accessible without charge, but its use is subject to the licensing conditions set by its authors or editors. Unless expressly stated otherwise in the licensing conditions, you are free to linking, browsing, printing and making a copy for your own personal purposes. All other acts of reproduction and communication to the public are subject to the licensing conditions expressed by editors and authors and require consent from them. Any link to this document should be made using its official URL in Dialnet. More info: https://dialnet.unirioja.es/info/derechosOAI
|